An observational study in Neovascular Age-related Macular Degeneration, sponsored by Clearside Biomedical, Inc.. Completed at 7 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-03-04.
Sponsored by Clearside Biomedical, Inc. · Observational
This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.
This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2. 3 and 4 of the Parent study, CLS1002-101. The Parent study is a 12-week, Phase 1/2a, multicenter study designed to assess the safety and tolerability of a single dose of CLS-AX administered suprachoroidally in subjects with neovascular age-related macular degeneration (nAMD) who show stable visual acuity following 3 or more injections with an intravitreal (IVT) anti-VEGF therapy in the preceding 5 months.
Summary analyses will include 12-weeks data from the Parent study, CLS1002-101, and 12-weeks data from this extension study, CLS1002-102, for a total of 24 weeks follow-up, for all participants enrolled into the extension study.
1,459 studies on the registry are indexed under Macular Degeneration; 238 are open to participants now.
This study's enrollment of 15 is below the median of 110 across 409 observational studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Clearside Biomedical, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants who completed cohort 2 or 3 or 4 of CLS1002-101
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who were administered by suprachoroidal injection 0.10 mg CLS-AX in cohort 2 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
Drug: CLS-AX
Subjects who were administered by suprachoroidal injection 0.50 mg CLS-AX in cohort 3 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
Drug: CLS-AX
Subjects who were administered by suprachoroidal injection 1.0 mg CLS-AX in cohort 4 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
Drug: CLS-AX
injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
Also known as: axitinib injectable suspension
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
The number of participants with treatment-emergent adverse events (TEAEs) reported between the administration of CLS-AX and study exit.
Time frame: Day 1 to Week 24
Number of Participants With Serious Adverse Events (SAEs)
The number of participants with serious adverse events (SAEs) reported between the administration of CLS-AX and study exit.
Time frame: Day 1 to Week 24
Mean Change From Baseline in Central Subfield Thickness (CST) in the Study Eye
Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A central reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema. Only images that were gradable by the central reading center were included in the analysis.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye
BCVA measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting test distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Number of Participants Receiving Additional Intravitreal (IVT) Aflibercept Injections
Number of participants receiving additional intravitreal aflibercept injections during the course of the study for nAMD.
Time frame: Day 1 to Week 24
Number of Participants Qualifying to Receive Additional Intravitreal (IVT) Aflibercept Injections
Number of participants qualifying to receive additional intravitreal aflibercept injections during the course of the study. Criteria included 1) loss of 10 or more letters in BCVA compared to the best prior study-assessed BCVA in the study eye that was attributed to intra- or sub-retinal fluid, 2) increase in central subfield thickness \>75 microns from Baseline in the study eye, or 3) presence of vision-threatening hemorrhage due to AMD in the study eye.
Time frame: Day 1 to Week 24
Mean Change From Baseline in Pre-Injection Intraocular Pressure (IOP)
Intraocular pressure (IOP) is a diagnostic measurement of the fluid pressure, measured in millimeters of mercury, inside the eye. IOP was measured using Goldmann applanation tonometry or by use of a Tonopen tonometer. Normal eye pressure is usually considered to be between 10 and 20 mmHg (AAO.org). Untreated elevated eye pressure is a risk factor for glaucoma.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
| Milestone | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension |
|---|---|---|---|
| Started | 3 | 7 | 5 |
| Safety population | 3 | 7 | 5 |
| Completed | 2 | 7 | 5 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
The number of participants with treatment-emergent adverse events (TEAEs) reported between the administration of CLS-AX and study exit.
| Participants | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 3 | 2 | 1 |
The number of participants with serious adverse events (SAEs) reported between the administration of CLS-AX and study exit.
| Participants | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 0 | 0 | 0 |
Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A central reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema. Only images that were gradable by the central reading center were included in the analysis.
| microns | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension |
|---|---|---|---|
| Week 4 | 14.7 ± 14.47 | 23.5 ± 23.82 | 20.2 ± 26.64 |
| Week 8 | 5.7 ± 30.37 | 28.2 ± 21.48 | 13.6 ± 18.08 |
| Week 12 | 53.3 ± 83.34 | 36.6 ± 34.02 | 19.4 ± 16.10 |
| Week 16 | 18.0 ± 19.80 | 5.1 ± 28.26 | 13.4 ± 15.49 |
| Week 20 | 67.0 | 20.0 ± 21.84 | 26.2 ± 49.55 |
| Week 24 | 6.0 | 20.4 ± 33.10 | 26.4 ± 65.26 |
BCVA measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting test distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.
| letters | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension |
|---|---|---|---|
| Week 4 | 0.7 ± 2.08 | 1.0 ± 2.19 | 0.8 ± 2.49 |
| Week 8 | -2.3 ± 2.08 | 2.5 ± 3.08 | 1.8 ± 2.86 |
| Week 12 | -5.0 ± 10.82 | -0.9 ± 2.85 | 0.0 ± 3.16 |
| Week 16 | -2.0 ± 0.00 | 1.9 ± 3.02 | 1.0 ± 4.85 |
| Week 20 | 0.0 ± 1.41 | 0.0 ± 2.65 | 1.0 ± 6.20 |
| Week 24 | -35.0 ± 46.67 | -1.9 ± 5.05 | 0.4 ± 6.62 |
Number of participants receiving additional intravitreal aflibercept injections during the course of the study for nAMD.
| Participants | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension |
|---|---|---|---|
| Week 4 | 1 | 0 | 1 |
| Week 8 | 1 | 0 | 0 |
| Week 12 | 1 | 1 | 1 |
| Week 16 | 0 | 0 | 0 |
| Week 20 | 1 | 0 | 2 |
| Week 24 | 0 | 2 | 1 |
| Day 1 to Week 24 | 3 | 2 | 3 |
Number of participants qualifying to receive additional intravitreal aflibercept injections during the course of the study. Criteria included 1) loss of 10 or more letters in BCVA compared to the best prior study-assessed BCVA in the study eye that was attributed to intra- or sub-retinal fluid, 2) increase in central subfield thickness \>75 microns from Baseline in the study eye, or 3) presence of vision-threatening hemorrhage due to AMD in the study eye.
| Participants | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension |
|---|---|---|---|
| Week 4 | 1 | 0 | 1 |
| Week 8 | 1 | 0 | 0 |
| Week 12 | 1 | 1 | 1 |
| Week 16 | 0 | 0 | 0 |
| Week 20 | 1 | 0 | 2 |
| Week 24 | 1 | 2 | 1 |
| Day 1 to Week 24 | 3 | 2 | 3 |
Intraocular pressure (IOP) is a diagnostic measurement of the fluid pressure, measured in millimeters of mercury, inside the eye. IOP was measured using Goldmann applanation tonometry or by use of a Tonopen tonometer. Normal eye pressure is usually considered to be between 10 and 20 mmHg (AAO.org). Untreated elevated eye pressure is a risk factor for glaucoma.
| mmHg | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension |
|---|---|---|---|
| Week 4 | -0.7 ± 4.16 | -0.5 ± 0.84 | 0.2 ± 5.45 |
| Week 8 | 0.3 ± 3.79 | 0.2 ± 1.72 | 1.6 ± 3.78 |
| Week 12 | 0.3 ± 2.31 | -0.1 ± 1.68 | 0.2 ± 3.90 |
| Week 16 | 0.5 ± 3.54 | 0.4 ± 1.72 | 1.2 ± 2.49 |
| Week 20 | 1.0 ± 0.00 | -0.6 ± 0.98 | 0.0 ± 3.54 |
| Week 24 | -1.0 ± 4.24 | 0.6 ± 1.99 | 0.4 ± 3.91 |
Collected over Adverse events were collected over 24 weeks following CLS-AX administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 2 (Low-mid Dose) Extension | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 3 (High-mid Dose) Extension | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Cohort 4 (High Dose) Extension | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Event | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension |
|---|---|---|---|
| Macular degenerationEye disorders | 1/3 | 0/7 | 0/5 |
| Retinal haemorrhageEye disorders | 1/3 | 1/7 | 0/5 |
| Subretinal fluidEye disorders | 1/3 | 0/7 | 0/5 |
| CystitisInfections and infestations | 1/3 | 0/7 | 0/5 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/3 | 0/7 | 0/5 |
| Transient ischaemic attackNervous system disorders | 1/3 | 0/7 | 0/5 |
| Ventricular extrasystolesCardiac disorders | 0/3 | 0/7 | 1/5 |
| COVID-19Infections and infestations | 0/3 | 0/7 | 1/5 |
| PneumoniaInfections and infestations | 0/3 | 0/7 | 1/5 |
| Conjunctival haemorrhageEye disorders | 0/3 | 1/7 | 0/5 |
| Age, Continuous(years) | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension | Total |
|---|---|---|---|---|
| Mean | 78.7 ± 9.02 | 87.9 ± 4.98 | 79.6 ± 3.97 | 83.3 ± 6.82 |
| Sex: Female, Male(Participants) | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension | Total |
|---|---|---|---|---|
| Female | 2 | 5 | 4 | 11 |
| Male | 1 | 2 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 7 | 5 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 3 | 7 | 5 | 15 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension | Total |
|---|---|---|---|---|
| United States | 3 | 7 | 5 | 15 |
| Duration of nAMD Diagnosis in the Study Eye(months) | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension | Total |
|---|---|---|---|---|
| Mean | 56.63 ± 23.759 | 67.29 ± 44.329 | 36.42 ± 38.955 | 54.87 ± 39.442 |
| Total Number of Prior nAMD Treatments in the Study Eye(Participants) | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension | Total |
|---|---|---|---|---|
| 0-2 Injections | 0 | 0 | 0 | 0 |
| 3-6 Injections | 0 | 2 | 1 | 3 |
| 7-12 Injections | 1 | 0 | 1 | 2 |
| 13-18 Injections | 0 | 1 | 0 | 1 |
| >18 Injections | 2 | 4 | 3 | 9 |
| Pre Injection Intraocular Pressure in the Study Eye at Baseline(mmHg) | Cohort 2 (Low-mid Dose) Extension | Cohort 3 (High-mid Dose) Extension | Cohort 4 (High Dose) Extension | Total |
|---|---|---|---|---|
| Mean | 14.3 ± 1.53 | 13.9 ± 2.34 | 13.8 ± 3.56 | 13.9 ± 2.52 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Jan 2023, 14 months.
Results were first posted in Mar 2024, 1 year 1 month after primary completion.
Of 56 industry-sponsored observational studies under Macular Degeneration, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 69. This study's 14 months is below that.
Counting every sponsor, half of 160 studies reached it within 45 months; a quarter within 16 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clearside Biomedical, Inc.